Literature DB >> 8428982

Carbohydrate residues modulate the activation of coagulation factor X.

U Sinha1, D L Wolf.   

Abstract

Factor X is a plasma protein involved in both the intrinsic and extrinsic pathways of blood coagulation. Post-translational modifications of the protein involve gamma-carboxylation of specific glutamic acid residues, beta-hydroxylation of one aspartic acid residue, and N- and O-linked glycosylation. Even though it is known that gamma-carboxylation is instrumental in regulating biological activity, the role of glycosylation in the function and properties of factor X has not been previously investigated. We utilized lectin binding and glycosidase treatment to investigate the functional role of carbohydrates on the activation peptide of factor X. Sambucus nigra agglutinin, a lectin that binds to sialic acid terminally linked alpha(2-6) to galactose or N-acetyl-galactosamine inhibits activation of human factor X in a dose-dependent manner. Inhibition of activation was observed for both intrinsic (factor IXa/VIIIa) and extrinsic (factor VIIa/tissue factor) pathway complexes. In accordance with this, selective removal of sialic acid residues on the activation peptide of factor X by neuraminidase also results in a drastic reduction of activation of the zymogen by these complexes. Corresponding reduction of activity in classical clotting assays (activated partial thromboplastin time and prothrombin time) also agrees with this observation. These results suggest a possible role of N-linked carbohydrates in the activation of factor X.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8428982

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Zymogenic and enzymatic properties of the 70-80 loop mutants of factor X/Xa.

Authors:  Lin Chen; Chandrashekhara Manithody; Likui Yang; Alireza R Rezaie
Journal:  Protein Sci       Date:  2004-02       Impact factor: 6.725

2.  Proteomic characterization of two snake venoms: Naja naja atra and Agkistrodon halys.

Authors:  Shuting Li; Jingqiang Wang; Xumin Zhang; Yan Ren; Ning Wang; Kang Zhao; Xishu Chen; Caifeng Zhao; Xiaolei Li; Jianmin Shao; Jianning Yin; Matthew B West; Ningzhi Xu; Siqi Liu
Journal:  Biochem J       Date:  2004-11-15       Impact factor: 3.857

3.  Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function.

Authors:  Jian-Ke Tie; Mei-Yan Zheng; R Marshall Pope; David L Straight; Darrel W Stafford
Journal:  Biochemistry       Date:  2006-12-12       Impact factor: 3.162

4.  Group D prothrombin activators from snake venom are structural homologues of mammalian blood coagulation factor Xa.

Authors:  Veena S Rao; Jeremiah S Joseph; R Manjunatha Kini
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

5.  Mass spectrometry based analysis of human plasma-derived factor X revealed novel post-translational modifications.

Authors:  Guillaume Chevreux; Nolwenn Tilly; Valegh Faid; Nicolas Bihoreau
Journal:  Protein Sci       Date:  2015-09-18       Impact factor: 6.725

6.  The missense Thr211Pro mutation in the factor X activation peptide of a bleeding patient causes molecular defect in the clotting cascade.

Authors:  Qiulan Ding; Yiping Shen; Likui Yang; Xuefeng Wang; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2013-05-16       Impact factor: 5.249

7.  Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X.

Authors:  L Yang; C Manithody; A R Rezaie
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

8.  Identification of the oligosaccharide structures of human coagulation factor X activation peptide at each glycosylation site.

Authors:  H Nakagawa; N Takahashi; K Fujikawa; Y Kawamura; M Iino; H Takeya; H Ogawa; K Suzuki
Journal:  Glycoconj J       Date:  1995-04       Impact factor: 2.916

9.  Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product.

Authors:  Lucia F Zacchi; Dinora Roche-Recinos; Cassandra L Pegg; Toan K Phung; Mark Napoli; Campbell Aitken; Vanessa Sandford; Stephen M Mahler; Yih Yean Lee; Benjamin L Schulz; Christopher B Howard
Journal:  Commun Biol       Date:  2021-03-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.